Related Experiment Video
Updated: May 17, 2026
Bacterial Expression and Purification of Human Matrix Metalloproteinase-3 using Affinity Chromatography
Published on: March 30, 2022
Development of a neutralizing antibody specific for the active form of matrix metalloproteinase-13
Shoichi Naito1, Tatsuya Takahashi, Junji Onoda
1Shionogi Pharmaceutical Research Center, Shionogi & Company, Ltd., 3-1-1 Futaba-cho, Toyonaka, Osaka 561-0825, Japan.
Abstract:
Matrix metalloproteinase-13 (MMP-13) is important in the pathology of osteoarthritis (OA). Although MMP-13 is considered a therapeutic target for OA, it is unclear how MMP-13 activity is regulated by the system that comprises various proteinases and their inhibitors. MMP-13 neutralizing antibodies could be a useful tool for investigating the involvement of MMP-13 in cartilage degeneration in OA-affected joints because antibodies possess high affinity and specificity compared with low-molecular weight chemical compounds. On the basis of three-dimensional structure and amino acid sequence information on MMP-13, we selected an appropriate antigen peptide and generated a neutralizing antibody by immunizing mice with the antigen. The most significant property of monoclonal antibody 14D10 was the specific binding to the active form of MMP-13, but not to the latent form, or other MMPs. With this property, active MMP-13 was measured selectively by an enzyme-linked immunosorbet assay. Furthermore, 14D10 suppressed the cleavage of type II collagen in human articular chondrocyte cultures, and 14D10 is thought to inhibit MMP-13 activity effectively. Thus, the highly selective MMP-13 neutralizing antibody (14D10) might be a useful tool for investigating the mechanism of type II collagen degradation in arthritic pathology.
Insights
A new monoclonal antibody, 14D10, specifically targets active matrix metalloproteinase-13 (MMP-13), a key enzyme in osteoarthritis. This antibody effectively inhibits MMP-13 activity and collagen cleavage, offering a valuable tool for OA research.
Area of Science:
- Biochemistry
- Immunology
- Rheumatology
Background:
- Matrix metalloproteinase-13 (MMP-13) plays a critical role in osteoarthritis (OA) pathogenesis.
- Understanding MMP-13 regulation is crucial for developing effective OA therapies.
- Existing methods for studying MMP-13 activity have limitations in specificity and affinity.
Purpose of the Study:
- To develop a highly specific neutralizing antibody against the active form of MMP-13.
- To investigate the utility of this antibody as a tool for studying MMP-13's role in cartilage degeneration.
- To assess the antibody's potential for therapeutic applications in OA.
Main Methods:
- Generated a monoclonal antibody (14D10) targeting an MMP-13 specific antigen peptide.
- Characterized antibody binding specificity using enzyme-linked immunosorbent assay (ELISA).
- Assessed the antibody's inhibitory effect on type II collagen cleavage in human chondrocyte cultures.
Main Results:
- Monoclonal antibody 14D10 demonstrated specific binding to the active form of MMP-13, not latent forms or other MMPs.
- Developed a selective ELISA assay for measuring active MMP-13 levels.
- 14D10 effectively suppressed type II collagen cleavage in vitro, indicating potent MMP-13 inhibition.
Conclusions:
- The highly selective MMP-13 neutralizing antibody, 14D10, is a valuable research tool.
- 14D10 facilitates the investigation of MMP-13's role in type II collagen degradation in arthritic conditions.
- This antibody holds promise for advancing OA research and therapeutic strategies.
More Related Videos
07:52Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Published on: September 10, 2018
11:10Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
Published on: June 29, 2016
